Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 8/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | BMP1 | P13497 | 2/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24616825 | 1.00 | PTPN1 (0.50) | PTPN1ACEGNPATBACE1BACE2 | |
| SCHEMBL22640907 | 0.95 | PTPN1 (0.47) | PTPN1ACEGNPATBACE1BACE2 | |
| SCHEMBL22640906 | 0.95 | PTPN1 (0.47) | PTPN1ACEGNPATBACE1BACE2 | |
| SCHEMBL24616810 | 0.95 | PTPN1 (0.47) | PTPN1ACEGNPATBACE1BACE2 | |
| SCHEMBL24616809 | 0.95 | PTPN1 (0.47) | PTPN1ACEGNPATBACE1BACE2 | |
| SCHEMBL22640932 | 0.95 | PTPN1 (0.47) | PTPN1ACEGNPATBACE1BACE2 | |
| SCHEMBL31497402 | 0.93 | PTPN1 (0.51) | PTPN1ACEGNPATBACE1BACE2 | |
| SCHEMBL24616731 | 0.93 | ACE (0.47) | PTPN1ACEGNPATBACE1BACE2 | |
| SCHEMBL22640912 | 0.93 | ACE (0.47) | PTPN1ACEGNPATBACE1BACE2 | |
| SCHEMBL24616717 | 0.93 | ACE (0.47) | PTPN1ACEGNPATBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3736284-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | Iproteos S.L (ES) | 2020-11-11 | — | — | EP | disclosed |